---
title: "Amgen Inc. Stock Outperforms Competitors On Strong Trading Day"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300481509.md"
description: "Amgen Inc. (AMGN) stock rose 1.32% to $423.64, outperforming competitors like Johnson & Johnson and Pfizer during a broader market decline on Tuesday. This marks the third consecutive day of gains for Amgen. Trading volume exceeded its 50-day average, though the stock remains 5.23% below its 52-week high."
datetime: "2026-09-29T20:34:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300481509.md)
  - [en](https://longbridge.com/en/news/300481509.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300481509.md)
generator: "portal-rs"
---

# Amgen Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Amgen Inc. (AMGN) rose 1.32% to $423.64 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.17% to 7,670.84 and Dow Jones Industrial Average falling 0.26% to 51,349.92.

This was the stock's third consecutive day of gains.

Amgen Inc. closed 5.23% below its 52-week high of $447.03, which the company achieved on August 25th.

The stock outperformed some of its competitors Tuesday, as Johnson & Johnson (JNJ) fell 1.61% to $267.57, Pfizer Inc. (PFE) remained unchanged, and AbbVie Inc. (ABBV) fell 1.12% to $263.29.

Trading volume (3.3 M) eclipsed its 50-day average volume of 2.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled September 29, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

09-29-26 1634ET

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)

## Related News & Research

- [How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story](https://longbridge.com/en/news/300175029.md)
- [Amgen reports a Phase 3 win with Sjögren’s drug candidate](https://longbridge.com/en/news/300046755.md)
- [Nilsine Partners LLC Makes New Investment in Amgen Inc. $AMGN](https://longbridge.com/en/news/298130227.md)
- [Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data](https://longbridge.com/en/news/299801248.md)
- [Will HDDs Be Replaced by SSDs? Investment Value Analysis of Seagate Technology and Western Digital in the AI Era](https://longbridge.com/en/news/300838673.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**